Kennedy suggested the requirement for CES is one reason why the US is lagging behind other parts of the world in the rollout ...

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion, in a deal that would give it control ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...